KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Dividends Paid - CommonExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kla (KLAC) Asset Writedowns and Impairment: 2015-2024

Historic Asset Writedowns and Impairment for Kla (KLAC) over the last 10 years, with Q4 2024 value amounting to $239.1 million.

  • Kla's Asset Writedowns and Impairment rose 917.81% to $239.1 million in Q4 2024 from the same period last year, while for Jun 2025 it was $239.1 million, marking a year-over-year decrease of 3357.37%. This contributed to the annual value of $239.1 million for FY2025, which is 1740.19% down from last year.
  • According to the latest figures from Q4 2024, Kla's Asset Writedowns and Impairment is $239.1 million, which was up 917.81% from $70.5 million recorded in Q1 2024.
  • In the past 5 years, Kla's Asset Writedowns and Impairment ranged from a high of $239.1 million in Q4 2024 and a low of -$23000.0 during Q1 2021
  • Over the past 5 years, Kla's median Asset Writedowns and Impairment value was $10.0 million (recorded in 2020), while the average stood at $69.4 million.
  • Its Asset Writedowns and Impairment has fluctuated over the past 5 years, first plummeted by 6513.5% in 2020, then surged by 58924.86% in 2021.
  • Kla's Asset Writedowns and Impairment (Quarter) stood at $865000.0 in 2020, then surged by 589.25% to $6.0 million in 2021, then skyrocketed by 53.57% to $9.2 million in 2022, then skyrocketed by 2291.87% to $219.0 million in 2023, then grew by 9.18% to $239.1 million in 2024.
  • Its Asset Writedowns and Impairment was $239.1 million in Q4 2024, compared to $70.5 million in Q1 2024 and $219.0 million in Q4 2023.